Oxytocin significantly improves survival and respiratory function in fentanyl and xylazine-fentanyl induced respiratory depression

The ongoing opioid crisis is exacerbated by the increasing co-administration of opioids with non-opioid respiratory depressants like xylazine, a veterinary tranquilizer. This combination leads to severe opioid induced respiratory depression (OIRD) that is often resistant to conventional treatments such as naloxone, a mu opioid receptor antagonist. Naloxone's limited efficacy against xylazine-potentiated respiratory depression creates a critical gap in overdose reversal strategies. This study investigates oxytocin (OXT) as a potential therapeutic agent to mitigate this life-threatening respiratory compromise.

Researchers tested oxytocin's ability to reverse severe OIRD and mortality in male and female rats. Animals were administered high doses of fentanyl or a combination of fentanyl and xylazine to induce respiratory depression. The study compared the effects of OXT administration against recovery using naloxone alone, particularly in the fentanyl-xylazine group. Additionally, chemogenetic activation of OXT receptor positive neurons within the ventral respiratory group (VRG) was performed to explore the underlying neural mechanisms of OXT's action on respiratory function.

Oxytocin demonstrated a robust ability to improve survival and respiratory function in rats experiencing OIRD induced by both fentanyl alone and the more challenging fentanyl-xylazine combination. The therapeutic effect of OXT was particularly notable in cases involving xylazine co-exposure. > The improvement in respiratory function by OXT post fentanyl-xylazine was significantly greater than the recovery observed using only naloxone, highlighting OXT's potential in scenarios where naloxone is only partially effective. Furthermore, direct chemogenetic activation of OXT receptor positive neurons in the VRG yielded similar beneficial effects, effectively reversing OIRD. This suggests a direct neural pathway through which oxytocin exerts its respiratory-protective effects, independent of systemic administration.